Pharma Update

Astegolimab: First-in-class anti-ST2 mAb in COPD Early results show benefit in key endpoints throughout broad patient population Astegolimab (anti-ST2 mAb) astegolimab (anti-ST2) IL-33 macrophage neutrophil anti IL-33 mast cell ST2* cells endothelium eosinophil progenitor eosinophil 48-week exacerbation rate 4 Ph lla (COPD-ST2OP) results¹ Exacerbation rate at 48 weeks RR 0.78 (95% CI 0-53-1-14) p=0.195 AERR=22% Adjusted mean change from baseline in SGRQ-C total score (95% CI) ANWAN SGRQ mean change from baseline Placebo group Astegolimab group Roche • • Astegolimab binds both soluble ST2 and • membrane bound ST2 (IL-33) receptor ⚫ IL-33/ST2 blockade may impact airway remodeling in COPD patients • #3 cause of global deaths; no biologics currently approved in COPD 24 0- Placebo group Astegolimab group Weeks Ph lla (COPD-ST20P): AER reduction of -22% (-37% in EOS low), reduction in SGRQ of -3.3 and increased FEV₁ by +40 ml . Safe and well tolerated • Earlier Ph Il results in asthma with AER reduction of -43% (-54% in EOS low) support efficacy and safety profile in broad population, including EOS low² 1 Yousuf et al. Lancet Respir. Med. 2022;10 (5):469-77; 2Kelsen et al. J Allergy Clin Immunol 2021;148(3)790-8; mAb-monoclonal antibody; ST2=suppression of tumorigenicity 2; IL-33-interleukin-33; COPD-chronic obstructive pulmonary disease; EOS-eosinophils; RR-rate reduction; AER(R)-annualized exacerbation rate (reduction); SGRQ-St. George's respiratory questionnaire; FEV₁-forced expiratory value 111

View entire presentation